Search CommunityWalk:


Amplimmune, Inc.

9800 Medical Center Drive, Suite C-120
Rockville, MD 20850, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Amplimmune, Inc. is engaged in the development of immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. It was founded in 2007, with a vision to develop drugs active in the treatment of cancer and infectious diseases involves selectively activating T cell populations to eradicate tumor or infection via either increasing T cell co-stimulation agonists and/or blocking immune checkpoints.

Amplimmune's co-stimulation/immune checkpoint inhibition portfolio provides unprecedented flexibility and versatility in modulating immune responses. The portfolio encompasses many of the B7 family members and patents covering their use as agonists to enhance co-stimulation or the application of antagonists to block members that induce inhibition.

Amplimmune's products include: AMP-110 for the treatment of autoimmune diseases; and AMP-224, a fusion protein that blocks the interaction between PD-1 and B7-H1, for treatment of cancer and chronic infections.

Amplimmune has collaborations with GlaxoSmithKline plc, National Institutes of Health, The National Cancer Institute, The U.S. Department of Health and Human Services, Fast Forward, LLC and The National Multiple Sclerosis Society. Its investors include: InterWest Partners and The Wellcome Trust.